Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia.
Secondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet generation. In this study we tested the effect of iron therapy on platelet counts...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3323537?pdf=render |
id |
doaj-fbc4be2315614261ab8820fa093f7692 |
---|---|
record_format |
Article |
spelling |
doaj-fbc4be2315614261ab8820fa093f76922020-11-24T22:11:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3452010.1371/journal.pone.0034520Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia.Stefanie Kulnigg-DabschRayko EvstatievClemens DejacoChristoph GascheSecondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet generation. In this study we tested the effect of iron therapy on platelet counts in patients with IBD-associated anemia.Platelet counts were analyzed before and after iron therapy from four prospective clinical trials. Further, changes in hemoglobin, transferrin saturation, ferritin, C-reactive protein, and leukocyte counts, before and after iron therapy were compared. In a subgroup the effect of erythropoietin treatment was tested. The results were confirmed in a large independent cohort (FERGIcor).A total of 308 patient records were available for the initial analysis. A dose-depended drop in platelet counts (mean 425 G/L to 320 G/L; p<0.001) was found regardless of the type of iron preparation (iron sulphate, iron sucrose, or ferric carboxymaltose). Concomitant erythropoietin therapy as well as parameters of inflammation (leukocyte counts, C-reactive protein) had no effect on the change in platelet counts. This effect of iron therapy on platelets was confirmed in the FERGIcor study cohort (n=448, mean platelet counts before iron therapy: 383 G/L, after: 310 G/L, p<0.001).Iron therapy normalizes elevated platelet counts in patients with IBD-associated anemia. Thus, iron deficiency is an important pathogenetic mechanism of secondary thrombocytosis in IBD.http://europepmc.org/articles/PMC3323537?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefanie Kulnigg-Dabsch Rayko Evstatiev Clemens Dejaco Christoph Gasche |
spellingShingle |
Stefanie Kulnigg-Dabsch Rayko Evstatiev Clemens Dejaco Christoph Gasche Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. PLoS ONE |
author_facet |
Stefanie Kulnigg-Dabsch Rayko Evstatiev Clemens Dejaco Christoph Gasche |
author_sort |
Stefanie Kulnigg-Dabsch |
title |
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
title_short |
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
title_full |
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
title_fullStr |
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
title_full_unstemmed |
Effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
title_sort |
effect of iron therapy on platelet counts in patients with inflammatory bowel disease-associated anemia. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Secondary thrombocytosis is a clinical feature of unknown significance. In inflammatory bowel disease (IBD), thrombocytosis is considered a marker of active disease; however, iron deficiency itself may trigger platelet generation. In this study we tested the effect of iron therapy on platelet counts in patients with IBD-associated anemia.Platelet counts were analyzed before and after iron therapy from four prospective clinical trials. Further, changes in hemoglobin, transferrin saturation, ferritin, C-reactive protein, and leukocyte counts, before and after iron therapy were compared. In a subgroup the effect of erythropoietin treatment was tested. The results were confirmed in a large independent cohort (FERGIcor).A total of 308 patient records were available for the initial analysis. A dose-depended drop in platelet counts (mean 425 G/L to 320 G/L; p<0.001) was found regardless of the type of iron preparation (iron sulphate, iron sucrose, or ferric carboxymaltose). Concomitant erythropoietin therapy as well as parameters of inflammation (leukocyte counts, C-reactive protein) had no effect on the change in platelet counts. This effect of iron therapy on platelets was confirmed in the FERGIcor study cohort (n=448, mean platelet counts before iron therapy: 383 G/L, after: 310 G/L, p<0.001).Iron therapy normalizes elevated platelet counts in patients with IBD-associated anemia. Thus, iron deficiency is an important pathogenetic mechanism of secondary thrombocytosis in IBD. |
url |
http://europepmc.org/articles/PMC3323537?pdf=render |
work_keys_str_mv |
AT stefaniekulniggdabsch effectofirontherapyonplateletcountsinpatientswithinflammatoryboweldiseaseassociatedanemia AT raykoevstatiev effectofirontherapyonplateletcountsinpatientswithinflammatoryboweldiseaseassociatedanemia AT clemensdejaco effectofirontherapyonplateletcountsinpatientswithinflammatoryboweldiseaseassociatedanemia AT christophgasche effectofirontherapyonplateletcountsinpatientswithinflammatoryboweldiseaseassociatedanemia |
_version_ |
1725805658486341632 |